Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.9K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

528
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
528

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identification of key metabolic enzymes involved in the activation of obeldesivir and remdesivir to the active triphosphate metabolite.

Antimicrobial agents and chemotherapy·2026
Same author

Oxidative DNA Damage Exacerbates the Mutagenic Potential of Alternative DNA Structures via Altered DNA Repair Processing.

Environmental and molecular mutagenesis·2026
Same author

Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis.

Journal of medicinal chemistry·2025
Same author

Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.

Lancet (London, England)·2025
Same author

Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway.

The Journal of pharmacology and experimental therapeutics·2024
Same author

Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability.

Antimicrobial agents and chemotherapy·2024

相关实验视频

Updated: Dec 16, 2025

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.9K

用长效小分子对艾滋病毒囊蛋白进行临床向

John O Link1, Martin S Rhee1, Winston C Tse1,2

  • 1Gilead Sciences, Foster City, CA, USA.

Nature
|July 3, 2020
PubMed
概括

一种新的长效注射性艾滋病毒囊抑制剂GS-6207显示出强大的抗病毒活性. 这种新疗法为经验丰富的人提供了有前途的治疗和预防方案.

更多相关视频

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.2K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K

相关实验视频

Last Updated: Dec 16, 2025

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.9K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.2K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K

科学领域:

  • 病毒学
  • 药理学
  • 药物开发

背景情况:

  • 口服抗逆转录病毒疗法对于艾滋病毒治疗和预防至关重要,但也面临药物耐药性和坚持性等挑战.
  • 经验丰富的患者由于多种药物耐药性,往往只有有限的治疗选择.
  • 每日口服治疗方案的不理想遵守可能导致治疗失败,耐药性和传播.

研究的目的:

  • 介绍一种新的小分子抑制剂GS-6207.
  • 评估GS-6207作为长效治疗艾滋病毒的潜力.
  • 在早期临床试验中评估GS-6207的安全性和有效性.

主要方法:

  • GS-6207是使用X射线结晶学设计的,以准HIV囊蛋白的保存接口.
  • 对各种HIV-1亚型进行了体外抗病毒活性测试.
  • 评估了与现有抗逆转录病毒药物的协同作用和交叉耐药性.
  • 一期临床研究评估了GS- 6207单次皮下注射剂的安全性,耐受性和药物动力学特征.

主要成果:

  • GS- 6207在所有测试的HIV-1亚型中表现出强烈的抗病毒活性.
  • 这种药物与已批准的抗逆转录病毒药物没有交叉耐药性.
  • 在第一阶段的研究中,单次450mg皮下注射的GS- 6207导致9天内平均病毒载量显著降低 (2. 2 log10).
  • 持续超过抗病毒活性水平的血度在治疗后的6个月内被观察到.

结论:

  • 作为一种治疗策略,GS-6207验证了向HIV囊蛋白的功能.
  • 这种药物具有很高的功效,良好的药动力学和长效性,使其成为长效艾滋病治疗和预防的有希望的候选药物.
  • 对于治疗选择有限的个体和暴露前预防来说,GS- 6207是一种潜在的新疗法.